Detailed Information on Publication Record
2022
Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program: Randomized Controlled Trial
MORAVCOVÁ, Katarína, Martina KARBANOVÁ, Maxi Pia BRETSCHNEIDER, Markéta SOVOVÁ, Jaromir OZANA et. al.Basic information
Original name
Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program: Randomized Controlled Trial
Authors
MORAVCOVÁ, Katarína (203 Czech Republic, guarantor), Martina KARBANOVÁ (203 Czech Republic, belonging to the institution), Maxi Pia BRETSCHNEIDER, Markéta SOVOVÁ (203 Czech Republic), Jaromir OZANA (203 Czech Republic) and Eliska SOVOVA (203 Czech Republic)
Edition
Nutrients, Basel, MDPI, 2022, 2072-6643
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30308 Nutrition, Dietetics
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.900
RIV identification code
RIV/00216224:14110/22:00125801
Organization unit
Faculty of Medicine
UT WoS
000801761100001
Keywords in English
obesity; diabetes mellitus type 2; prevention; digital therapeutics; mobile application; randomized controlled trial; lifestyle intervention; metabolic syndrome; insulin resistance
Tags
International impact, Reviewed
Změněno: 25/1/2023 09:59, Mgr. Tereza Miškechová
Abstract
V originále
In this study, we evaluated whether the digital program Vitadio achieves comparable results to those of an intensive in-person lifestyle intervention in obesity management. This is a 12-month prospective, randomized controlled trial. Obese patients with insulin resistance, prediabetes or type 2 diabetes were included. The intervention group (IG) used Vitadio. The control group (CG) received a series of in-person consultations. Body weight and various metabolic parameters were observed and analyzed with ANOVA. The trial is ongoing and the presented findings are preliminary. Among 100 participants (29% men; mean age, 43 years; mean BMI, 40.1 kg/m2), 78 completed 3-month follow-up, and 51 have completed the 6-month follow-up so far. Participants significantly (p < 0.01) reduced body weight at 3 months (IG: −5.9 ± 5.0%; CG: −4.2 ± 5.0%) and 6 months (IG: −6.6±6.1%; CG: −7.1 ± 7.1%), and the difference between groups was not significant. The IG achieved favorable change in body composition; significant improvement in TAG (−0.6 ± 0.9 mmol/l, p < 0.01), HDL (0.1 ± 0.1%, p < 0.05), HbA1c (−0.2 ± 0.5%, p < 0.05) and FG (−0.5 ± 1.5 mmol/l, p < 0.05); and a superior (p = 0.02) HOMA-IR reduction (−2.5 ± 5.2, p < 0.01). The digital intervention achieved comparable results to those of the intensive obesity management program. The results suggest that Vitadio is an effective tool for supporting patients in obesity management and diabetes prevention.